Kraig Biocraft Laboratories, Inc.

What they do

The company develops high-strength fibers using recombinant DNA technology, inserting spider silk gene sequences into domesticated mulberry silkworms so the resulting germline transformation is self-perpetuating. Its fibers combine native silkworm silk proteins with spider silk proteins, and the company describes the technology as a protein expression platform with potential uses beyond textiles, including diagnostics and pharmaceutical production. Target applications cited include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and ballistic-resistant materials.

Revenue drivers

• Recombinant spider silk fiber — The company's core product line is engineered silkworm-produced spider silk fiber for specialty fiber and technical textile markets; no segment revenue is broken out in the reported financials, and the last reported annual revenue was $401,620 in 2018.
• Future fashion wear line — Management states it plans to create a line of recombinant spider silk fashion wear either under its own brand or in partnership with existing commercial entities; this has not yet generated reported revenue.
• Protein expression platform — The company describes its silk technology as a protein expression platform with potential applications in diagnostics and pharmaceutical production, but no revenue or commercial agreements are reported for this area.

Recent performance

The company reported no annual revenue in 2014 or 2015 and no quarterly revenue in the sampled periods, with the most recent annual revenue shown at $401,620 in 2018. Annual net losses were $8.0M in 2021, $3.8M in 2022, $3.0M in 2023, $3.4M in 2024 and $3.6M in 2025. Operating cash flow was negative each year, at -$1.8M in 2021, -$1.9M in 2022, -$1.2M in 2023, -$1.8M in 2024 and -$1.8M in 2025. At June 30, 2026, total assets were $4.3M, total liabilities were $11.0M, shareholder equity was -$6.8M and cash and equivalents were $3.4M.

Strategy

Management's stated plan for the next twelve months is to accelerate and expand commercial-scale production of recombinant spider silk. It also plans to expand research and development into next-generation materials, improve the robustness of its silk lines, and create a recombinant spider silk fashion wear line under its own brand or through partnerships. The company intends to continue expanding overseas production operations, including work with local contractors or cooperatives and additional direct staff, and to advance microbiology research for more advanced spider silk and non-spider silk fibers. Management says it will consider buying an established revenue-producing company in a compatible business, noting that as of the filing date it has had no formal discussions or definitive agreements for any such purchase.

Risks

• Going concern — The independent auditor's report for fiscal 2024 and 2025 includes an explanatory paragraph stating that net losses from operations and net capital deficiency raise substantial doubt about the company's ability to continue as a going concern.
• No recent reported revenue — The most recent annual revenue shown in the financial data is $401,620 for 2018, and sampled quarterly revenue figures through 2021 are $0.00, indicating the company has not yet established recurring commercial sales.
• Negative equity and accumulated losses — At June 30, 2026, total liabilities of $11.0M exceeded total assets of $4.3M, producing shareholder equity of -$6.8M, and annual net losses have been roughly $3M to $8M per year from 2021 through 2025.
• Commercialization and production scale — The company's plans depend on expanding commercial-scale production of recombinant spider silk and overseas operations, which it has not yet demonstrated at revenue-generating volume.

Outlook

Management expects to spend the next twelve months accelerating commercial-scale production and expanding research and development of recombinant spider silk. It also plans to develop a fashion wear line, expand overseas production with local contractors or cooperatives, and pursue more advanced materials through microbiology research. The company says it may acquire an established revenue-producing business in a compatible field, though no formal discussions or agreements were in place as of the filing.